AboutValuesWhy OA.mg?OA.mg PremiumExploreDataContact
Chrome ExtensionScholarMindChatGPT Plugin
ϟ
 
DOI: 10.1016/j.jaad.2020.11.022
¤ OpenAccess: Hybrid
This work has “Hybrid” OA status. This means it is free under an open license in a toll-access journal.

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial

Andrew Blauvelt,Mark Lebwohl,Tomotaka Mabuchi,Ann N. Leung,Alyssa Garrelts,Heidi M. Crane,Hany Elmaraghy,Himanshu J. Patel,Terri Ridenour,Kyoungah See,Gaia Gallo,C. Paul

Medicine
Ixekizumab
Adverse effect
2021
Loading...
    Cite this:
Generate Citation
Powered by Citationsy*
    “Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial” is a paper by Andrew Blauvelt Mark Lebwohl Tomotaka Mabuchi Ann N. Leung Alyssa Garrelts Heidi M. Crane Hany Elmaraghy Himanshu J. Patel Terri Ridenour Kyoungah See Gaia Gallo C. Paul published in 2021. It has an Open Access status of “hybrid”. You can read and download a PDF Full Text of this paper here.
    OA.mgAbout UsOur ValuesWhy OA.mg? OA.mg PremiumChrome ExtensionChatGPT PluginPublic RoadmapChangelogContact UsFeedback?
    Privacy PolicyTerms of ServiceRefund Policy
    ContentOA.mg CoverageTop ListsOpen Access JournalsTopicsBlog
    ExploreGeographyEngineeringPoliSciGeologyPhilosophySociologyArtHistoryMathematicsPhysics
     PsychologyComputer ScienceBusinessEnvironmental ScienceChemistryMaterials ScienceMedicineBiologyEconomics
    OA.mg is built in Stockholm, London, and Seoul. We work hand in hand with the scientific community to advance the cause of Open Access. Feedback makes us better.